230 related articles for article (PubMed ID: 30804480)
1. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
Nat Nanotechnol; 2019 Apr; 14(4):388-397. PubMed ID: 30804480
[TBL] [Abstract][Full Text] [Related]
2. TP53 loss creates therapeutic vulnerability in colorectal cancer.
Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
[TBL] [Abstract][Full Text] [Related]
3. Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of
Xu J; Liu Y; Liu S; Ou W; White A; Stewart S; Tkaczuk KHR; Ellis LM; Wan J; Lu X; He X
Nano Today; 2022 Apr; 43():. PubMed ID: 35251293
[TBL] [Abstract][Full Text] [Related]
4. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
5. pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer.
Dong Y; Liao H; Fu H; Yu J; Guo Q; Wang Q; Duan Y
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38417-38428. PubMed ID: 31556584
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
Chen G; Wang Y; Xie R; Gong S
J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
[TBL] [Abstract][Full Text] [Related]
7. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
Valcourt DM; Dang MN; Scully MA; Day ES
ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
11. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
12. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
13. Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release.
Stras S; Howe A; Prasad A; Salerno D; Bhatavdekar O; Sofou S
Mol Pharm; 2020 Jan; 17(1):118-131. PubMed ID: 31825626
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
15. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
[TBL] [Abstract][Full Text] [Related]
16. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
17. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA.
Zhang L; Mu C; Zhang T; Yang D; Wang C; Chen Q; Tang L; Fan L; Liu C; Shen J; Li H
J Nanobiotechnology; 2021 Jan; 19(1):13. PubMed ID: 33413427
[TBL] [Abstract][Full Text] [Related]
18. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
[TBL] [Abstract][Full Text] [Related]
19. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
20. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]